About Us
- Home
- About
We are T cells R Us
Seal Team 6 of T cell therapy
Agile, tenacious, dedicated assembly of individuals, developing, from the ground up, the immunologic basis for translating into the clinic, TCR-based therapies over the last 25 years.
…. before TIL was effective, before CAR-T cells were invented, before cell therapy mad a blip on the cancer treatment landscape. We could fit an entire Cell therapy Symposium audience, in a freight elevator, and still have room for a whiteboard overhead projector and axe-throwing range.
What Happens When T Cells Are Missing in the Body
Without T cells, other immune cells like B cells, macrophages, and dendritic cells would still play a role in defense, but the immune response would be significantly less effective. B cells might produce antibodies, but they rely on T cell signals to activate fully. Macrophages could still engulf pathogens, but without T cells, they wouldn’t coordinate a targeted immune response. The overall immunity would be weaker, and the body would struggle to fight off infections and diseases effectively.
The Calm Before the Dance
They’d be sitting around the dance hall,Waiting for the band to show up, that’s what.The atmosphere thick with anticipation,
Feet tapping, hearts racing, ready to rock.
General Knowledge Base
Non-engineered adoptive cell transfer (ACT) is a cancer
immunotherapy modality rooted in the premise that there
are endogenous/existing tumor-reactive T cells that can be
isolated and expanded in suffi cient quantity and quality for
infusion into patients, with the expectation that they will
kill tumor cells and provide long-term immunoprotection.
When combined with a lymphodepleting preconditioning
regimen and a rapid expansion protocol, tumorinfi ltrating lymphocyte (TIL) therapy has achieved durable
responses in a subset of patients with advanced cancers,
in particular metastatic melanoma.
Endogenous T cell (ETC) therapy sources tumor antigenspecifi c T cells from the peripheral blood and can
achieve durable responses without the use of high-dose
lymphodepleting preconditioning regimens or postinfusion high-dose Interleukin-2 (IL-2)
Challenges to application of ACT to broader patient
populations include the identifi cation of immunogenic
target antigens while minimizing off-tumor toxicity,
poor traffi cking to and infi ltration of tumor sites, and an
immune-evasive, hostile tumor microenvironment.
Combination of ACT with therapies such as checkpoint
blockade, oncolytic viruses, or low-dose radiotherapy, as
well as intrinsic strategies that infl uence T cell phenotype
and function, may be used to increase the effi cacy of ACT
by promoting antigen spreading, improved traffi cking,
function, and in vivo persistence
T cells have potential for antitumor activity against
a broad range of tumor types, and their major
histocompatibility complex (MHC)-independence
reduces requirements for human leukocyte antigen
(HLA)-matching while enabling them to treat tumors
that escape the conventional T cell response via MHC
downregulation.
Endogenous T cell (ETC) therapy sources tumor antigenspecifi c T cells from the peripheral blood and can
achieve durable responses without the use of high-dose
lymphodepleting preconditioning regimens or postinfusion high-dose Interleukin-2 (IL-2)
Challenges to application of ACT to broader patient
populations include the identifi cation of immunogenic
target antigens while minimizing off-tumor toxicity,
poor traffi cking to and infi ltration of tumor sites, and an
immune-evasive, hostile tumor microenvironment.
T cells
Add beautiful boxes with title, image and button and encourage users to take action.
Create your own
The Power of T Cells: Advocating for Immune System Dominance
